On the stock market since 2018, it operates in the world of health and science. It has 797 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 127% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades below its recent peak — about 10% off the top. A pullback, not a collapse.
Over the last 3 years, sales grew about 49% a year on average.
Sales run at $366.4M a year. A small number, but proof the product has real buyers.
There is $345.0M in the vault; even if every debt were paid off, $317.3M would remain.
A loss of $6.1M against $366.4M in annual sales.
Over the last 12 months, executives reported 56 sells against just 8 buys. Not an alarm bell by itself, but a number worth watching.
On our five-subject report card, AXNX sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: AXNX is a high-risk stock — not yet profitable, and its future rides on its product catching on.